JP2007508527A5 - - Google Patents

Download PDF

Info

Publication number
JP2007508527A5
JP2007508527A5 JP2006530040A JP2006530040A JP2007508527A5 JP 2007508527 A5 JP2007508527 A5 JP 2007508527A5 JP 2006530040 A JP2006530040 A JP 2006530040A JP 2006530040 A JP2006530040 A JP 2006530040A JP 2007508527 A5 JP2007508527 A5 JP 2007508527A5
Authority
JP
Japan
Prior art keywords
organ damage
end organ
marker
level
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006530040A
Other languages
English (en)
Japanese (ja)
Other versions
JP4840744B2 (ja
JP2007508527A (ja
Filing date
Publication date
Priority claimed from EP03078161A external-priority patent/EP1522857A1/en
Application filed filed Critical
Publication of JP2007508527A publication Critical patent/JP2007508527A/ja
Publication of JP2007508527A5 publication Critical patent/JP2007508527A5/ja
Application granted granted Critical
Publication of JP4840744B2 publication Critical patent/JP4840744B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006530040A 2003-10-09 2004-09-27 ガレクチン−３またはトロンボスポンジン−２のレベルを定量することによって心不全を発症する危険性がある対象を同定する方法 Expired - Fee Related JP4840744B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03078161A EP1522857A1 (en) 2003-10-09 2003-10-09 Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
EP03078161.1 2003-10-09
PCT/EP2004/010879 WO2005040817A1 (en) 2003-10-09 2004-09-27 Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2010167334A Division JP2010279378A (ja) 2003-10-09 2010-07-26 ガレクチン−３またはトロンボスポンジン−２のレベルを定量することによって心不全を発症する危険性がある対象を同定する方法
JP2011088342A Division JP5580774B2 (ja) 2003-10-09 2011-04-12 ガレクチン−３またはトロンボスポンジン−２のレベルを定量することによって心不全を発症する危険性がある対象を同定する方法

Publications (3)

Publication Number Publication Date
JP2007508527A JP2007508527A (ja) 2007-04-05
JP2007508527A5 true JP2007508527A5 (https=) 2007-08-02
JP4840744B2 JP4840744B2 (ja) 2011-12-21

Family

ID=34306912

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2006530040A Expired - Fee Related JP4840744B2 (ja) 2003-10-09 2004-09-27 ガレクチン−３またはトロンボスポンジン−２のレベルを定量することによって心不全を発症する危険性がある対象を同定する方法
JP2010167334A Withdrawn JP2010279378A (ja) 2003-10-09 2010-07-26 ガレクチン−３またはトロンボスポンジン−２のレベルを定量することによって心不全を発症する危険性がある対象を同定する方法
JP2011088342A Expired - Lifetime JP5580774B2 (ja) 2003-10-09 2011-04-12 ガレクチン−３またはトロンボスポンジン−２のレベルを定量することによって心不全を発症する危険性がある対象を同定する方法
JP2014021394A Expired - Lifetime JP5789009B2 (ja) 2003-10-09 2014-02-06 ガレクチン−３またはトロンボスポンジン−２のレベルを定量することによって心不全を発症する危険性がある対象を同定する方法
JP2015081540A Pending JP2015171365A (ja) 2003-10-09 2015-04-13 ガレクチン−３またはトロンボスポンジン−２のレベルを定量することによって心不全を発症する危険性がある対象を同定する方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2010167334A Withdrawn JP2010279378A (ja) 2003-10-09 2010-07-26 ガレクチン−３またはトロンボスポンジン−２のレベルを定量することによって心不全を発症する危険性がある対象を同定する方法
JP2011088342A Expired - Lifetime JP5580774B2 (ja) 2003-10-09 2011-04-12 ガレクチン−３またはトロンボスポンジン−２のレベルを定量することによって心不全を発症する危険性がある対象を同定する方法
JP2014021394A Expired - Lifetime JP5789009B2 (ja) 2003-10-09 2014-02-06 ガレクチン−３またはトロンボスポンジン−２のレベルを定量することによって心不全を発症する危険性がある対象を同定する方法
JP2015081540A Pending JP2015171365A (ja) 2003-10-09 2015-04-13 ガレクチン−３またはトロンボスポンジン−２のレベルを定量することによって心不全を発症する危険性がある対象を同定する方法

Country Status (14)

Country Link
US (5) US7888137B2 (https=)
EP (4) EP1522857A1 (https=)
JP (5) JP4840744B2 (https=)
CN (2) CN102998458B (https=)
AT (1) ATE532073T1 (https=)
AU (2) AU2004284496C1 (https=)
CA (2) CA2542033C (https=)
CY (2) CY1112359T1 (https=)
DK (2) DK2317324T3 (https=)
ES (2) ES2530567T3 (https=)
PL (2) PL1682907T3 (https=)
PT (2) PT1682907E (https=)
SI (2) SI2317324T1 (https=)
WO (1) WO2005040817A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
US8153376B2 (en) 2006-09-25 2012-04-10 Universiteit Maastricht Means and methods for diagnosing and/or treating a subject at risk of developing heart failure
US20100055723A1 (en) * 2007-01-23 2010-03-04 University Of Virginia Patent Foundation Galectin-3-Binding Protein as a Biomarker of Cardiovascular Disease
CA2698899A1 (en) * 2007-09-17 2009-03-26 Bg Medicine, Inc. Assessing congestive heart risk in patients treated or potentially to be treated with a peroxisome-proliferator-activator-receptor-gamma agonist or a thiazolidinedione
CN104198712A (zh) * 2008-10-29 2014-12-10 Bg医药股份有限公司 半乳凝素-3免疫测定法
BR112012008063A2 (pt) * 2009-08-25 2016-11-22 Bg Medicine Inc galectina-3 e terapia de ressincronização cardíaca.
EP2588111A1 (en) 2010-07-02 2013-05-08 BG Medicine, Inc. Statin therapy monitored by galectin- 3 measurement
JP5787895B2 (ja) * 2010-10-18 2015-09-30 原　英彰 筋萎縮性側索硬化症マーカー及びその利用
EP2460890A1 (en) * 2010-12-01 2012-06-06 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Gpnmb/Osteoactivin as a drug target and biomarker in cardiac diseases
US20120220671A1 (en) * 2011-01-31 2012-08-30 Bg Medicine, Inc. Use of galectin-3 for detecting and prognosing heart failure after acute coronary syndrome
ES2750126T3 (es) 2011-03-17 2020-03-25 Critical Care Diagnostics Inc Procedimientos de predicción del riesgo de un resultado clínico adverso
AR086543A1 (es) * 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
CA2858601C (en) * 2011-12-08 2020-11-17 Isaac Eliaz Reduction of galectin-3 levels by plasmapheresis
US20150253314A1 (en) * 2012-09-27 2015-09-10 Siemens Healthcare Diagnostics Inc. Cystatin c and galectin-3 as biomarkers for pulmonary arterial hypertension
WO2014078655A1 (en) * 2012-11-15 2014-05-22 Tufts University Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor
CA2973653A1 (en) 2015-01-18 2016-07-21 Diasorin S.P.A. Use of 1,25-dihydroxyvitamin d values in ratio with pth as a prognostic biomarker
JP6612864B2 (ja) * 2015-05-28 2019-11-27 京セラ株式会社 切削工具
CN112553335A (zh) * 2020-12-17 2021-03-26 核工业总医院 肾细胞癌生物标志物及其应用
CA3238590A1 (en) * 2021-11-09 2023-05-19 Truebinding, Inc. Methods of treating or inhibiting cardiovascular diseases

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4632901A (en) * 1984-05-11 1986-12-30 Hybritech Incorporated Method and apparatus for immunoassays
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
AU2684488A (en) * 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US20010051350A1 (en) * 1995-05-02 2001-12-13 Albert Nazareth Diagnostic detection device and method
BE1010935A7 (nl) * 1997-02-19 1999-03-02 Delanghe Joris Richard Siegfri Fenotypering van humaan haptoglobine in serum of plasma door middel van quantitatieve agglutinatie met streptococcus antigenen.
CA2293718A1 (en) * 1997-06-10 1998-12-17 Medlyte Diagnostics, Inc. Methods for early detection of heart disease
US20060166276A1 (en) * 1997-09-05 2006-07-27 Lung Health Diagnostics Pty Ltd Method of diagnosis and agents useful for same
ATE476662T1 (de) * 1997-09-05 2010-08-15 Southern Medical Diagnostics P Diagnoseverfahren
DE69830668T3 (de) * 1997-10-24 2011-07-14 Shionogi & Co., Ltd. Verfahren zur inhibierung des abbaus von natriuretischen peptiden und verbesserte methode zum bestimmen der natriuretischen peptide
JP5030329B2 (ja) * 1998-04-02 2012-09-19 ジェネンテック， インコーポレイテッド 心臓肥大の処置
JP3987284B2 (ja) * 1999-01-29 2007-10-03 ロシュ ダイアグノスティックス ゲーエムベーハー Ｎ末端ｐｒｏＢＮＰの同定方法
AU3704500A (en) * 1999-02-19 2001-01-22 University Of Iowa Research Foundation, The Diagnostics and therapeutics for arterial wall disruptive disorders
JP2003507076A (ja) * 1999-08-20 2003-02-25 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム 心臓の遺伝子発現の調節におけるｈｄａｃ４およびｈｄａｃ５
WO2001057252A2 (en) 2000-02-04 2001-08-09 Aeomica, Inc. Methods and apparatus for high-throughput detection and characterization of alternatively spliced genes
JP2004532602A (ja) 2000-04-05 2004-10-28 インサイト・ゲノミックス・インコーポレイテッド 泡沫細胞分化において発現される遺伝子
KR100395254B1 (ko) 2000-10-30 2003-08-21 (주)자리타 바이오텍 종양 발생 예측 키트
US20030166017A1 (en) * 2000-11-09 2003-09-04 Millennium Pharmaceuticals, Inc. Compositions and methods for the identification, assessment, prevention and therapy of cardiovascular disease
WO2002038794A2 (en) * 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
DE60144493D1 (de) * 2000-12-08 2011-06-01 Curagen Corp Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
JP4035562B2 (ja) * 2001-01-31 2008-01-23 国立大学法人富山大学 ガレクチン−３誘導能を利用した物質のスクリーニング方法、肝の状態の診断方法およびこれらの方法を利用したキット
US7041449B2 (en) * 2001-03-19 2006-05-09 Wisconsin Alumni Research Foundation Methods of screening for compounds that inhibit expression of biomarker sequences differentially expressed with age in mice
US20060019235A1 (en) * 2001-07-02 2006-01-26 The Board Of Trustees Of The Leland Stanford Junior University Molecular and functional profiling using a cellular microarray
US7447594B2 (en) * 2001-07-10 2008-11-04 Ocimum Biosolutions, Inc. Molecular cardiotoxicology modeling
US20030099958A1 (en) * 2001-09-05 2003-05-29 Vitivity, Inc. Diagnosis and treatment of vascular disease
GB0124145D0 (en) 2001-10-08 2001-11-28 Bayer Ag Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
US20060141493A1 (en) * 2001-11-09 2006-06-29 Duke University Office Of Science And Technology Atherosclerotic phenotype determinative genes and methods for using the same
CA2483105C (en) * 2002-05-13 2011-05-10 Arexis Ab Autoimmune conditions and nadph oxidase defects
EP1579383A4 (en) 2002-10-24 2006-12-13 Univ Duke BINARY PREDICTION TREE MODELING WITH MANY PREDICTORS AND USES THEREOF FOR CLINICAL AND GENETIC APPLICATIONS
AU2003298689A1 (en) 2002-11-21 2004-06-18 Wyeth Methods for diagnosing rcc and other solid tumors
EP1431399A1 (en) * 2002-12-20 2004-06-23 Clinigenetics Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions
US6889083B2 (en) * 2003-04-21 2005-05-03 Medtronic, Inc. Atrial tracking recovery to restore cardiac resynchronization therapy in dual chamber tracking modes
US20070105105A1 (en) * 2003-05-23 2007-05-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
US20060257946A1 (en) * 2003-06-06 2006-11-16 Ciphergen Biosystems, Inc Serum biomarkers in ischaemic heart disease
US20050106100A1 (en) 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
EP1560025A3 (en) * 2003-10-03 2011-09-07 F. Hoffmann-La Roche AG Specific markers for diabetes
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
DE10347436B4 (de) * 2003-10-13 2007-08-02 Johann Wolfgang Goethe-Universität Frankfurt am Main In vitro Verfahren zur Diagnose der kardiovaskulären Funktionalität von Blut-abgeleiteter zirkulierender Vorläuferzellen (BDP)
WO2005070446A1 (en) 2004-01-15 2005-08-04 Scios Inc. Method for treating cardiac remodeling following myocardial injury
WO2006026074A2 (en) 2004-08-04 2006-03-09 Duke University Atherosclerotic phenotype determinative genes and methods for using the same
US20090258002A1 (en) 2005-02-01 2009-10-15 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for Tissue Status
WO2006102497A2 (en) * 2005-03-22 2006-09-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for diagnosis, monitoring and development of therapeutics for treatment of atherosclerotic disease
US7632634B2 (en) * 2005-04-15 2009-12-15 University Of Maryland Biotechnology Institute Method and assay for early diagnosis of prostate cancer
US9592970B2 (en) * 2008-07-17 2017-03-14 Toby D. Henderson Robotic gantry with end effector for product lifting
CN104198712A (zh) * 2008-10-29 2014-12-10 Bg医药股份有限公司 半乳凝素-3免疫测定法
BR112012008063A2 (pt) * 2009-08-25 2016-11-22 Bg Medicine Inc galectina-3 e terapia de ressincronização cardíaca.

Similar Documents

Publication Publication Date Title
JP2007508527A5 (https=)
US10132809B2 (en) Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis
WO2004046729A3 (en) Bodily fluid markers of tissue hypoxia
JP6941324B2 (ja) 新規な肝硬変または肝線維症のマーカー
WO2007011412A3 (en) Diagnosis and prognosis of infectious diesease clinical phenotypes and other physiologic states using host gene expresion biomarkers in blood
JP2011177182A5 (https=)
EP1849002A4 (en) Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
JP2010506147A5 (https=)
RU2009139295A (ru) Биомаркеры и биомаркерные признаки почечной сохранности, обладающие предсказательной силой, для использования в мониторинге состояния почек
EP2339348A3 (en) Method for diagnosing neuro-degenerative disease
PE20121029A1 (es) Marcadores de riesgo para enfermedad cardiovascular
EP1838867A4 (en) APOLIPOPROTEIN A II ISOFORM AS A BIOMARKER FOR PROSTATE CANCER
WO2008122670A3 (en) Human diabetes susceptibility tnfrsf10b gene
ATE531820T1 (de) Gesundheitszustandstest
JP2009524829A5 (https=)
ATE447715T1 (de) Automatische glykofingerabdruck-strategie
JP2009515556A5 (https=)
JP2009511905A5 (https=)
RU2008103988A (ru) Способ диагностики рассеяного склероза
JP2010538252A5 (https=)
JP2006508326A5 (https=)
FR2930036B1 (fr) Procede de diagnostic d'une hypertension arterielle pulmonaire.
WO2003068268A3 (en) Treatment, diagnosis and imaging of disease
JP2007536913A5 (https=)
ATE498023T1 (de) Verfahren zur erkennung des fortschritts einer zervikalen dysplasie niedrigen grades